
Top 3 Pharma Stocks to Watch in 2027: Divi's Labs, Mankind Pharma and Aurobindo Pharma
Divi's Labs Rs 11,049.00, Q2 PAT +63.6%. Mankind Pharma Rs 2,625.00, Q2 PAT +37.7%. Aurobindo Pharma Rs 1,796.30, Q2 PAT +32.5%. Prices as of 18 Nov 2026.
Updated: 19 Nov 2026 • 1:09 pm
Posted by:

Quick Answer
The pharma stocks to watch in 2027 are Divi's Laboratories, Mankind Pharma and Aurobindo Pharma, based on their latest results, returns and balance sheets. Divi's Labs leads on both recent profit growth and return on equity, while Aurobindo Pharma is the most attractively valued. The best figures in the group are 63.6% quarterly profit growth, a PE of 25.99 and a return on equity of 18.69%. Each stock has its own risks, so investors should match the choice to their holding period and risk appetite.
The pharma stocks to watch in 2027 are best picked on reported numbers. US generic launches, contract manufacturing for global drug makers and steady domestic demand are driving Indian pharma, and the three companies on this list grew September 2026 quarter profit by more than 32%.
This list covers Divi's Laboratories, Mankind Pharma and Aurobindo Pharma. Each company is assessed on quarterly and annual profit growth, return on equity, debt, valuation and where its share price sits in its 52-week range. Prices are as of the 18 November 2026 close.
Click Here – Get Free Investment Predictions
Top 3 Pharma Stocks to Watch in 2027 at a Glance
Divi's Labs, Mankind Pharma and Aurobindo Pharma have a combined market capitalisation of about Rs 5.07 lakh crore. The table below compares these pharma stocks to watch in 2027 on the metrics that matter most for long-term investors.
| Metric | Divi's Labs | Mankind Pharma | Aurobindo Pharma |
|---|---|---|---|
| Company | Divi's Laboratories | Mankind Pharma | Aurobindo Pharma |
| NSE Symbol | DIVISLAB | MANKIND | AUROPHARMA |
| Share Price (Rs) | 11,049.00 | 2,625.00 | 1,796.30 |
| 52-Week Closing High (Rs) | 11,565.50 | 2,668.30 | 1,855.30 |
| 52-Week Closing Low (Rs) | 5,821.00 | 1,927.40 | 1,121.70 |
| Market Cap (Rs Cr) | 2,93,874 | 1,09,040 | 1,03,626 |
| PE Ratio | 87.39 | 48.17 | 25.99 |
| ROE | 18.69% | 12.76% | 10.13% |
| Debt to Equity | 0.00 | 0.31 | 0.22 |
| Dividend Yield | 0.27% | 0.04% | 0.22% |
On valuation, the stocks trade at the following PE ratios: Divi's Labs at 87.39 against an industry PE of 40.12; Mankind Pharma at 48.17 against an industry PE of 40.12; Aurobindo Pharma at 25.99 against an industry PE of 40.12. Aurobindo Pharma trades below the industry multiple, while Divi's Labs and Mankind Pharma carry a premium that the market usually pays for faster growth or stronger returns.
Why Are These the Pharma Stocks to Watch in 2027?
These three made the list of pharma stocks to watch in 2027 because of earnings delivery and balance sheet quality. Indian pharma companies earn money in three main ways: selling branded medicines in India, exporting generic drugs to the US and Europe, and manufacturing ingredients or drugs for global pharma companies under contract. The three stocks on this list each lead one of these models.
In the September 2026 quarter, net profit grew 63.6% at Divi's Labs, 37.7% at Mankind Pharma and 32.5% at Aurobindo Pharma. Return on equity ranges from 10.13% to 18.69%, which shows how efficiently each company uses shareholder capital. Divi's Labs runs with little or no debt.
What Could Drive Pharma Stocks in 2027?
Pharma stocks in 2027 will be driven by new US generic approvals, pricing pressure in the US generics market, growth in chronic therapies in India, and contract manufacturing orders as global drug makers diversify their supply chains.
US FDA inspection outcomes are a key risk to track, since a warning letter can delay approvals from a plant. Divi's Laboratories and Aurobindo Pharma are constituents of the Nifty Pharma, so their results move the sector index.
1. Divi's Laboratories: Contract Manufacturing Leader with Debt-Free Balance Sheet
Divi's Laboratories makes active pharmaceutical ingredients and custom-synthesised molecules for global pharma companies, and it is one of the world's largest makers of several generic APIs.
Divi's Labs Financial Performance
| Metric | Latest | Year Earlier | Change |
|---|---|---|---|
| Revenue (Rs Cr) | 3,770 | 2,860 | +31.8% |
| Net Profit (Rs Cr) | 1,127 | 689 | +63.6% |
| Revenue FY26 vs FY25 (Rs Cr) | 11,067 | 9,712 | +14.0% |
| Net Profit FY26 vs FY25 (Rs Cr) | 2,568 | 2,191 | +17.2% |
For FY26, revenue came in at Rs 11,067 crore (+14.0%), and net profit rose 17.2% to Rs 2,568 crore.
What to Watch in Divi's Labs for 2027
Divi's Labs grew September 2026 quarter net profit 63.6% to Rs 1,127 crore on 31.8% higher revenue, the fastest in this group, and it has the highest ROE at 18.69% with no debt. Its PE of 87.39 is far above the industry PE of 40.12, so investors should be careful about valuation and track new custom synthesis contracts. The stock closed at Rs 11,049.00 on 18 November 2026, about 4.5% below its 52-week closing high of Rs 11,565.50 and 89.8% above its 52-week closing low of Rs 5,821.00.
2. Mankind Pharma: Domestic Branded Medicines Leader
Mankind Pharma is one of India's largest domestic pharma companies by sales volume, known for brands such as Manforce, Prega News and Gas-O-Fast, with a strong presence in smaller towns.
Mankind Pharma Financial Performance
| Metric | Latest | Year Earlier | Change |
|---|---|---|---|
| Revenue (Rs Cr) | 4,432.71 | 3,789.03 | +17.0% |
| Net Profit (Rs Cr) | 716.12 | 520.18 | +37.7% |
| Revenue FY26 vs FY25 (Rs Cr) | 14,636.43 | 12,744.23 | +14.8% |
| Net Profit FY26 vs FY25 (Rs Cr) | 1,938.10 | 2,006.59 | Lower YoY |
For FY26, revenue came in at Rs 14,636.43 crore (+14.8%), and net profit stood at Rs 1,938.10 crore. Net profit has compounded at about 7.5% a year from FY22 to FY26.
What to Watch in Mankind Pharma for 2027
Mankind Pharma grew September 2026 quarter net profit 37.7% to Rs 716.12 crore on 17.0% higher revenue. Investors should track the integration of its Bharat Serums and Vaccines acquisition, which added women's health and critical care products. The stock closed at Rs 2,625.00 on 18 November 2026, about 1.6% below its 52-week closing high of Rs 2,668.30 and 36.2% above its 52-week closing low of Rs 1,927.40.
Compare Pharma Stocks on the Univest Screener
3. Aurobindo Pharma: US Generics Leader at the Lowest PE
Aurobindo Pharma is one of the largest Indian exporters of generic medicines to the US and Europe, with a wide portfolio of oral, injectable and biosimilar products.
Aurobindo Pharma Financial Performance
| Metric | Latest | Year Earlier | Change |
|---|---|---|---|
| Revenue (Rs Cr) | 10,431.51 | 8,406.29 | +24.1% |
| Net Profit (Rs Cr) | 1,123.84 | 848.13 | +32.5% |
| Revenue FY26 vs FY25 (Rs Cr) | 34,145.17 | 32,345.58 | +5.6% |
| Net Profit FY26 vs FY25 (Rs Cr) | 3,502.97 | 3,483.57 | +0.6% |
For FY26, revenue came in at Rs 34,145.17 crore (+5.6%), and net profit rose 0.6% to Rs 3,502.97 crore. Net profit has compounded at about 7.3% a year from FY22 to FY26.
What to Watch in Aurobindo Pharma for 2027
Aurobindo Pharma grew September 2026 quarter net profit 32.5% to Rs 1,123.84 crore and revenue 24.1% to Rs 10,431.51 crore. It trades at a PE of 25.99, the lowest of the three and below the industry PE of 40.12. Investors should track US FDA inspection outcomes and its biosimilars pipeline. The stock closed at Rs 1,796.30 on 18 November 2026, about 3.2% below its 52-week closing high of Rs 1,855.30 and 60.1% above its 52-week closing low of Rs 1,121.70.
How Do Divi's Labs, Mankind Pharma and Aurobindo Pharma Compare?
The table below puts quarterly growth, annual profit, valuation and price position for the three pharma stocks side by side.
| Metric | Divi's Labs | Mankind Pharma | Aurobindo Pharma |
|---|---|---|---|
| Q2 Net Profit Growth | +63.6% | +37.7% | +32.5% |
| Latest Annual Net Profit (Rs Cr) | 2,568 | 1,938.10 | 3,502.97 |
| PE vs Industry PE | 87.39 vs 40.12 | 48.17 vs 40.12 | 25.99 vs 40.12 |
| Distance from 52-Week Closing High | 4.5% below | 1.6% below | 3.2% below |
For investors building a list of pharma stocks to watch in 2027, the right pick depends on priorities. Those who want growth momentum and capital efficiency may track Divi's Labs and investors who want valuation comfort may prefer Aurobindo Pharma. Mankind Pharma gives exposure to a different part of the sector.
Key Risks for Pharma Stocks in 2027
Even the strongest pharma stocks to watch in 2027 carry risks that investors should weigh before buying.
US pricing pressure: Price erosion in US generics can reduce margins even when volumes grow.
Regulatory action: US FDA warning letters or import alerts can stop shipments from a plant.
Currency moves: A stronger rupee reduces the value of export revenue.
Valuation: Divi's Labs and Mankind Pharma trade above the industry PE, so a slowdown in growth can lead to price corrections. Staggered buying helps manage entry risk.
Download the Univest iOS App or Univest Android App to track Divi's Labs, Mankind Pharma and Aurobindo Pharma live and get daily stock research.
Conclusion
Divi's Laboratories, Mankind Pharma and Aurobindo Pharma stand out among pharma stocks to watch in 2027 on growth, returns and balance sheet strength. Before investing, compare each stock's PE with its profit growth, check where it trades in its 52-week range, and track the December and March quarter results to confirm the trend into 2027. Building positions gradually suits a sector where earnings can swing with US pricing pressure.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Pharma Stocks to Watch in 2027
Which are the best pharma stocks to watch in 2027?
Ans. Divi's Laboratories, Mankind Pharma and Aurobindo Pharma are three of the strongest pharma stocks to watch in 2027 based on reported numbers. Divi's Labs leads on both recent profit growth and return on equity, while Aurobindo Pharma is the most attractively valued. The strongest figures in the group are 63.6% quarterly profit growth, a 18.69% return on equity and a PE of 25.99. Each company covers a different part of the pharma space, so the best choice depends on whether an investor prefers growth, value or capital efficiency. Investors should match the pick to their own risk profile and holding period.
Which pharma stock has grown profit the fastest?
Ans. Divi's Laboratories has grown profit the fastest among these three, with September 2026 quarter net profit up 63.6% year on year to Rs 1,127 crore. Mankind Pharma follows with 37.7% growth. Divi's Labs's latest annual net profit stood at Rs 2,568 crore for FY26. Quarterly growth can swing with seasonality and one-time items, so investors should compare several quarters before drawing conclusions. Margins and demand trends over the next two quarters will show whether this pace can continue into 2027.
Which of these pharma stocks is the most attractively valued?
Ans. Aurobindo Pharma is the most attractively valued of the three, with a PE of 25.99 against an industry PE of 40.12. Mankind Pharma trades at 48.17 and Divi's Labs at 87.39. A lower PE can signal value, but it can also reflect slower growth or higher risk, so it should be read with profit growth and return on equity. Investors should also check where each stock trades within its 52-week range before deciding on an entry point.
Which pharma stock has the lowest valuation?
Ans. Aurobindo Pharma has the lowest valuation of the three with a PE of 25.99, against an industry PE of 40.12. Mankind Pharma trades at 48.17 and Divi's Laboratories at 87.39. Aurobindo's lower PE reflects its exposure to the price-competitive US generics market, while Divi's commands a premium for its contract manufacturing model and debt-free balance sheet. Investors should compare profit growth and return on equity along with the PE before deciding, since Divi's also grew quarterly profit the fastest at 63.6%.
What are the key risks for pharma stocks in 2027?
Ans. The main risks for pharma stocks in 2027 are US pricing pressure, regulatory action and currency moves. Price erosion in US generics can reduce margins even when volumes grow. Valuation is another risk, since Divi's Labs and Mankind Pharma trade above the industry PE. US FDA warning letters or import alerts can stop shipments from a plant. A stronger rupee reduces the value of export revenue. Investors should review quarterly results, avoid putting too much money into a single stock, and size positions according to their risk tolerance.
Should I invest in pharma stocks for the long term?
Ans. Pharma stocks can suit long-term investors who understand the sector's cycles and are comfortable with price swings. Divi's Labs, Mankind Pharma and Aurobindo Pharma have shown profit growth and healthy returns on equity, which are good signs for long-term holders. Divi's Labs earns a 18.69% return on equity, which shows how efficiently it uses shareholder money. Building positions gradually, for example through staggered purchases, usually works better than buying a full position at once. Before investing, check your asset allocation and consider speaking with a SEBI-registered investment adviser.
Recent Articles

Ahlada Engineers Analyst Review 2027: Revenue Jumps 87% but Profit Stays Near Zero
19 November 2026

Agro Phos Analyst Review 2027: Sales and Profit Slip in Q2 as Stock Nears Yearly Low
19 November 2026

Agri-Tech India Analyst Review 2027: Tiny Revenue and Steady Losses, but Stock at Half of Book
19 November 2026

Agarwal Industrial Analyst Review 2027: Q2 Profit Up 30% but Stock Sits 51% Below Its High
19 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Ahlada Engineers Analyst Review 2027: Revenue Jumps 87% but Profit Stays Near Zero
Agro Phos Analyst Review 2027: Sales and Profit Slip in Q2 as Stock Nears Yearly Low
Agri-Tech India Analyst Review 2027: Tiny Revenue and Steady Losses, but Stock at Half of Book
Agarwal Industrial Analyst Review 2027: Q2 Profit Up 30% but Stock Sits 51% Below Its High
Akme Fintrade Analyst Review 2027: AUM Crosses ₹1,000 Crore as Profit Rises 19%
Popular this week
Affordable Robotic Analyst Review 2027: Q2 Rebound to ₹6.47 Crore Profit on ₹149 Crore Order Book

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





